In addition, proteomic analyses have identified other EV-associated biomarkers, showing that IL-4, IL-6, and oncostatin M levels were elevated, whereas neurturin and MCP-1 levels were reduced in EVs from AAA patients [75]. This evidence concerns the gene CCL2 and triple-A syndrome.